Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Thinking Critically: How to Teach Translational Medicine.

Foty RG, Gibbs EM, Lips EH, Menon M, Hafler JP.

Front Public Health. 2018 Oct 10;6:284. doi: 10.3389/fpubh.2018.00284. eCollection 2018.

2.

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.

Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, Bierman C, van Leeuwen FE, Rutgers EJ, Schmidt MK, Lips EH, Wesseling J.

Clin Cancer Res. 2018 Aug 1;24(15):3593-3601. doi: 10.1158/1078-0432.CCR-18-0201. Epub 2018 Apr 23.

PMID:
29685879
3.

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.

Sobral-Leite M, Lips EH, Vieira-Monteiro HA, Giacomin LC, Freitas-Alves DR, Cornelissen S, Mulder L, Wesseling J, Schmidt MK, Vianna-Jorge R.

PLoS One. 2017 Dec 21;12(12):e0189750. doi: 10.1371/journal.pone.0189750. eCollection 2017.

4.

Enrichment of high-grade tumors in breast cancer gene expression studies.

van Seijen M, Mooyaart AL, Mulder L, Hoogstraat M, Drukker CA, Loo CE, Pouw B, Sonke GS, Wesseling J, Lips EH.

Breast Cancer Res Treat. 2018 Apr;168(2):327-335. doi: 10.1007/s10549-017-4622-9. Epub 2017 Dec 18.

5.

Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages.

Kersten K, Coffelt SB, Hoogstraat M, Verstegen NJM, Vrijland K, Ciampricotti M, Doornebal CW, Hau CS, Wellenstein MD, Salvagno C, Doshi P, Lips EH, Wessels LFA, de Visser KE.

Oncoimmunology. 2017 Jun 19;6(8):e1334744. doi: 10.1080/2162402X.2017.1334744. eCollection 2017.

6.

Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.

Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH.

BMC Cancer. 2016 Oct 19;16(1):811.

7.

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).

Groen EJ, Elshof LE, Visser LL, Rutgers EJT, Winter-Warnars HAO, Lips EH, Wesseling J.

Breast. 2017 Feb;31:274-283. doi: 10.1016/j.breast.2016.09.001. Epub 2016 Sep 23. Review.

8.

BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency.

Lips EH, Debipersad RD, Scheerman CE, Mulder L, Sonke GS, van der Kolk LE, Wesseling J, Hogervorst FB, Nederlof PM.

Clin Cancer Res. 2017 Mar 1;23(5):1236-1241. doi: 10.1158/1078-0432.CCR-16-0198. Epub 2016 Sep 12.

9.

[Ductal carcinoma in situ: the balance between over- and undertreatment].

Groen EJ, Elshof LE, Rutgers EJ, Winter-Warnars HA, Lips EH, Wesseling J.

Ned Tijdschr Geneeskd. 2016;160:A9773. Review. Dutch.

PMID:
27071361
10.

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJ, Koudijs MJ, Cuppen E, Voest EE, Bernards R, Nederlof PM, Wesseling J, Rodenhuis S, Wessels LF; Center for Personalized Cancer Treatment.

Breast Cancer Res. 2015 Oct 3;17(1):134. doi: 10.1186/s13058-015-0642-8.

11.

Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.

Wijdeven RH, Pang B, van der Zanden SY, Qiao X, Blomen V, Hoogstraat M, Lips EH, Janssen L, Wessels L, Brummelkamp TR, Neefjes J.

Cancer Res. 2015 Oct 1;75(19):4176-87. doi: 10.1158/0008-5472.CAN-15-0380. Epub 2015 Aug 10.

12.

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.

Jebbink M, van Werkhoven E, Mandjes IA, Wesseling J, Lips EH, Vrancken Peeters MJ, Loo CE, Sonke GS, Linn SC, Falo Zamora C, Rodenhuis S.

Breast Cancer Res Treat. 2015 Aug;153(1):145-52. doi: 10.1007/s10549-015-3510-4. Epub 2015 Jul 26.

PMID:
26210520
13.

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

Schouten PC, Grigoriadis A, Kuilman T, Mirza H, Watkins JA, Cooke SA, van Dyk E, Severson TM, Rueda OM, Hoogstraat M, Verhagen CV, Natrajan R, Chin SF, Lips EH, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Krijgsman O, Vens C, Peeper D, Nederlof PM, Caldas C, Tutt AN, Wessels LF, Linn SC.

Mol Oncol. 2015 Aug;9(7):1274-86. doi: 10.1016/j.molonc.2015.03.002. Epub 2015 Mar 20.

14.

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.

Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, de Vries EG, van Tinteren H, Jonkers J, Hauptmann M, Rodenhuis S, Linn SC.

Breast Cancer Res. 2014 May 15;16(3):R47. doi: 10.1186/bcr3655.

15.

Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.

Pengel KE, Koolen BB, Loo CE, Vogel WV, Wesseling J, Lips EH, Rutgers EJ, Valdés Olmos RA, Vrancken Peeters MJ, Rodenhuis S, Gilhuijs KG.

Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1515-24. doi: 10.1007/s00259-014-2770-2. Epub 2014 Apr 29.

PMID:
24777490
16.

Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypes.

de Ronde JJ, Bonder MJ, Lips EH, Rodenhuis S, Wessels LF.

PLoS One. 2014 Feb 18;9(2):e88551. doi: 10.1371/journal.pone.0088551. eCollection 2014.

17.

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.

Rigter LS, Loo CE, Linn SC, Sonke GS, van Werkhoven E, Lips EH, Warnars HA, Doll PK, Bruining A, Mandjes IA, Vrancken Peeters MJ, Wesseling J, Gilhuijs KG, Rodenhuis S.

Br J Cancer. 2013 Dec 10;109(12):2965-72. doi: 10.1038/bjc.2013.661. Epub 2013 Oct 22.

18.

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, Wessels LF, Rodenhuis S, Wesseling J.

Breast Cancer Res Treat. 2013 Jul;140(1):63-71. doi: 10.1007/s10549-013-2620-0. Epub 2013 Jul 5.

19.

Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.

Schouten PC, van Dyk E, Braaf LM, Mulder L, Lips EH, de Ronde JJ, Holtman L, Wesseling J, Hauptmann M, Wessels LF, Linn SC, Nederlof PM.

Breast Cancer Res Treat. 2013 Jun;139(2):317-27. doi: 10.1007/s10549-013-2558-2. Epub 2013 May 14.

PMID:
23670131
20.

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.

Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S, Nederlof PM.

Br J Cancer. 2013 May 28;108(10):2172-7. doi: 10.1038/bjc.2013.144. Epub 2013 Apr 4.

21.

SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.

de Ronde JJ, Lips EH, Mulder L, Vincent AD, Wesseling J, Nieuwland M, Kerkhoven R, Vrancken Peeters MJ, Sonke GS, Rodenhuis S, Wessels LF.

Breast Cancer Res Treat. 2013 Jan;137(1):213-23. doi: 10.1007/s10549-012-2340-x. Epub 2012 Dec 1.

PMID:
23203637
22.

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E; I-SPY TRIAL Investigators.

Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub 2012 Sep 8.

23.

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy.

Koolen BB, Vrancken Peeters MJ, Wesseling J, Lips EH, Vogel WV, Aukema TS, van Werkhoven E, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1830-8. doi: 10.1007/s00259-012-2211-z. Epub 2012 Aug 16.

PMID:
22895862
24.

Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.

Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH.

Ann Oncol. 2012 Sep;23(9):2301-5. doi: 10.1093/annonc/mdr621. Epub 2012 Feb 21.

PMID:
22357256
25.

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.

Lips EH, Laddach N, Savola SP, Vollebergh MA, Oonk AM, Imholz AL, Wessels LF, Wesseling J, Nederlof PM, Rodenhuis S.

Breast Cancer Res. 2011 Oct 27;13(5):R107. doi: 10.1186/bcr3049.

26.

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.

Breast Cancer Res Treat. 2012 Feb;131(3):827-36. doi: 10.1007/s10549-011-1488-0. Epub 2011 Apr 7.

PMID:
21472434
27.

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.

Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EG, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC.

Ann Oncol. 2011 Jul;22(7):1561-70. doi: 10.1093/annonc/mdq624. Epub 2010 Dec 6.

28.

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.

Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MT, van de Vijver MJ, Wesseling J, Nederlof PM, Rodenhuis S.

Ann Oncol. 2011 Apr;22(4):870-6. doi: 10.1093/annonc/mdq468. Epub 2010 Oct 11.

PMID:
20937646
29.

Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues.

van Eijk R, van Puijenbroek M, Chhatta AR, Gupta N, Vossen RH, Lips EH, Cleton-Jansen AM, Morreau H, van Wezel T.

J Mol Diagn. 2010 Jan;12(1):27-34. doi: 10.2353/jmoldx.2010.090028. Epub 2009 Dec 3.

30.

Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals.

Lips EH, Gaborieau V, McKay JD, Chabrier A, Hung RJ, Boffetta P, Hashibe M, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Field JK, Liloglou T, Xinarianos G, McLaughlin J, Liu G, Skorpen F, Elvestad MB, Hveem K, Vatten L, Study E, Benhamou S, Lagiou P, Holcátová I, Merletti F, Kjaerheim K, Agudo A, Castellsagué X, Macfarlane TV, Barzan L, Canova C, Lowry R, Conway DI, Znaor A, Healy C, Curado MP, Koifman S, Eluf-Neto J, Matos E, Menezes A, Fernandez L, Metspalu A, Heath S, Lathrop M, Brennan P.

Int J Epidemiol. 2010 Apr;39(2):563-77. doi: 10.1093/ije/dyp288. Epub 2009 Sep 23.

31.

The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression.

Pittman AM, Naranjo S, Webb E, Broderick P, Lips EH, van Wezel T, Morreau H, Sullivan K, Fielding S, Twiss P, Vijayakrishnan J, Casares F, Qureshi M, Gómez-Skarmeta JL, Houlston RS.

Genome Res. 2009 Jun;19(6):987-93. doi: 10.1101/gr.092668.109. Epub 2009 Apr 24.

32.

Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis.

Lips EH, van Eijk R, de Graaf EJ, Oosting J, de Miranda NF, Karsten T, van de Velde CJ, Eilers PH, Tollenaar RA, van Wezel T, Morreau H.

BMC Cancer. 2008 Oct 29;8:314. doi: 10.1186/1471-2407-8-314.

33.

High frequency of copy-neutral LOH in MUTYH-associated polyposis carcinomas.

Middeldorp A, van Puijenbroek M, Nielsen M, Corver WE, Jordanova ES, ter Haar N, Tops CM, Vasen HF, Lips EH, van Eijk R, Hes FJ, Oosting J, Wijnen J, van Wezel T, Morreau H.

J Pathol. 2008 Sep;216(1):25-31. doi: 10.1002/path.2375.

PMID:
18506705
34.

Progression and tumor heterogeneity analysis in early rectal cancer.

Lips EH, van Eijk R, de Graaf EJ, Doornebosch PG, de Miranda NF, Oosting J, Karsten T, Eilers PH, Tollenaar RA, van Wezel T, Morreau H.

Clin Cancer Res. 2008 Feb 1;14(3):772-81. doi: 10.1158/1078-0432.CCR-07-2052.

35.

Single nucleotide polymorphism array analysis of chromosomal instability patterns discriminates rectal adenomas from carcinomas.

Lips EH, de Graaf EJ, Tollenaar RA, van Eijk R, Oosting J, Szuhai K, Karsten T, Nanya Y, Ogawa S, van de Velde CJ, Eilers PH, van Wezel T, Morreau H.

J Pathol. 2007 Jul;212(3):269-77.

PMID:
17471469
36.

High-resolution copy number analysis of paraffin-embedded archival tissue using SNP BeadArrays.

Oosting J, Lips EH, van Eijk R, Eilers PH, Szuhai K, Wijmenga C, Morreau H, van Wezel T.

Genome Res. 2007 Mar;17(3):368-76. Epub 2007 Jan 31.

37.

Reliable high-throughput genotyping and loss-of-heterozygosity detection in formalin-fixed, paraffin-embedded tumors using single nucleotide polymorphism arrays.

Lips EH, Dierssen JW, van Eijk R, Oosting J, Eilers PH, Tollenaar RA, de Graaf EJ, van't Slot R, Wijmenga C, Morreau H, van Wezel T.

Cancer Res. 2005 Nov 15;65(22):10188-91.

38.

Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles.

de Bruin EC, van de Pas S, Lips EH, van Eijk R, van der Zee MM, Lombaerts M, van Wezel T, Marijnen CA, van Krieken JH, Medema JP, van de Velde CJ, Eilers PH, Peltenburg LT.

BMC Genomics. 2005 Oct 14;6:142.

Supplemental Content

Support Center